Researchers from Memorial Sloan-Kettering Hospital in New York have revealed that an experimental new drug for skin cancer has worked beyond expectations in a new study.
The study of 31 patients tested the drug called PLX4032 and found that it improved quality of life and extended lifespan as well.The drug is thought to act by blocking the activity of the BRAF gene, which is involved in the spread of skin cancer.
"We've seen responses in patients who didn't respond to chemotherapy before. So far 70 per cent of patients have responded. So that is unprecedented for us," said lead researchers Dr Paul Chapman.
The details of the study were presented at a cancer conference organized by the European Cancer Organisation in Berlin.